However, given that both models lack the endogenous regulatory regions and genomic context of DUX4, these models are not ideal for studies of FSHD genetics and/or epigenetics, and cannot be used to evaluate antisense oligonucleotide-based therapeutics that target the untranslated regions of the DUX4 transcript. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.